Article
Radiology, Nuclear Medicine & Medical Imaging
S. Cheenu Kappadath, Benjamin P. Lopez
Summary: This study proposes a method to model organ doses following intra-hepatic-arterial administration of Tc-99m-macroaggregated-albumin (IHA Tc-99m-MAA). The results show that the liver and lung receive the highest doses in the maximum-dose scenario.
Article
Radiology, Nuclear Medicine & Medical Imaging
Benedikt M. Schaarschmidt, Moritz Wildgruber, Roman Kloeckner, James Nie, Verena Steinle, Arthur J. A. T. Braat, Fabian Lohoefer, Hyun S. Kim, Harald Lahner, Manuel Weber, Jens Theysohn
Summary: Y-90 radioembolization (Y-90 RE) could be an important alternative treatment option for neuroendocrine neoplasms (NENs) patients with hepatic metastases, but more clinical evidence is needed.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Chemistry, Inorganic & Nuclear
Jaya Shukla, Ankita Goyal, Anupriya Chhabra, Yogesh Rathore, Kavita Bansal, Somit Pandey, Madan Parmar, Sonal Singhal, Naveen Kalra, Ajay Duseja, Bhagwant Rai Mittal
Summary: A microsphere cold kit for facile and quick radiolabeling with 188Re has been developed, showing good retention of 188Re microspheres in tumors and suitability for selective-intra-arterial radionuclide therapy (SIRT).
APPLIED RADIATION AND ISOTOPES
(2022)
Review
Oncology
Stephan Walrand, Michel Hesse, Philippe D'Abadie, Francois Jamar
Summary: Liver radioembolization is a treatment option for unresectable liver cancers, involving infusion of Y-90 or Ho-166 loaded spheres into the hepatic artery. While attempts to improve tumoral cell killing with arterial vasoconstrictors have been hindered by physiological responses like the hepatic arterial buffer response and hepatic vascular escape mechanism, a new approach involving co-infusion of a mesenteric arterial vasodilator has shown promise in animal studies. This new method aims to significantly increase the tumoral to normal tissue dose ratio, potentially moving the therapy towards curative intent, especially in hepatocellular carcinoma (HCC) cases where other delivery methods may not be feasible.
Article
Chemistry, Applied
Yunxia Wang, Chuangxin Zhang, Ying Li, Ruipeng Li, Jianfang Li, Liheng Feng
Summary: In this study, a type I photosensitizer called MTOTPy was developed by rational molecular design, which exhibited aggregation-induced near-infrared emission and specific identification ability. MTOTPy showed strong near-infrared fluorescence and efficient type I reactive oxygen species generation in an aggregated state due to enhanced electron-donating effect and electron-rich anion structure. It was demonstrated that MTOTPy could selectively identify tumor cells by targeting mitochondria and specifically recognize Staphylococcus aureus among other microbes. Moreover, under visible light irradiation at low concentrations of 5.0 μM and 0.5 μM, MTOTPy killed more than 90% of tumor cells and S. aureus, respectively. This work provides a feasible approach for designing photosensitizers to overcome hypoxia in photodynamic therapy and advance the development of efficient image-guided therapy.
Review
Oncology
Justin Kwan, Uei Pua
Summary: Liver is the most common site of metastasis in colorectal cancer patients, with surgery being the only potential curative option for a small percentage of patients. Advances in modern chemotherapy and personalized biological agents have improved overall survival in patients with unresectable liver metastasis. Liver-directed intra-arterial therapies are increasingly being considered to improve local tumor response and reduce systemic side effects in patients with dominant liver metastatic disease or limited extrahepatic disease.
Article
Nanoscience & Nanotechnology
Hannah J. Vaughan, Camila G. Zamboni, Kathryn M. Luly, Ling Li, Kathleen L. Gabrielson, Laboni F. Hassan, Nicholas P. Radant, Pranshu Bhardwaj, Florin M. Selaru, Martin G. Pomper, Jordan J. Green
Summary: This study investigated a new approach of local delivery of polymeric nanoparticles (NPs) via intra-arterial injection for targeted local gene delivery to hepatocellular carcinoma (HCC) tumors. The results showed that this method had a better effect in treating HCC compared to intravenous administration.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Article
Nanoscience & Nanotechnology
Lina Yu, Guanxiong Zhu, Zeyu Zhang, Zidan Xu, Weijie Peng, Liting Zeng, Yang Yu, Siran Wang, Zhongxiao Lin, Xin Zhang, Na Zhou, Lingmin Zhang, Lu Liang
Summary: The use of macrophage membrane-coated Verteporfin-loaded nanoparticles shows potential for effective photodynamic therapy in oral cancer treatment, displaying efficient cellular uptake and cytotoxic effects.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Review
Immunology
Zunyi Zhang, Erlei Zhang
Summary: Hepatocellular carcinoma (HCC) is a common type of liver cancer with high mortality rate. A significant percentage of HCC patients have vascular invasion at initial diagnosis. Traditional guidelines classify HCC with vascular invasion as advanced stage, limiting surgical options. However, recent advancements in systemic and locoregional treatments have shown promising responses, leading to the proposal of a conversion therapy strategy to eventually enable surgical resection. This review summarizes the clinical experience and evidence of conversion treatment in HCC patients with vascular invasion.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Andrew M. Vekstein, David C. Wendell, Sophia DeLuca, Ruorong Yan, Yifan Chen, Muath Bishawi, Garth W. Devlin, Aravind Asokan, Kenneth D. Poss, Dawn E. Bowles, Adam R. Williams, Nenad Bursac
Summary: Based on the study, direct intra-myocardial injection has the highest retention rate of nanoparticles, while catheter-based intra-coronary delivery with balloon occlusion and distal infusion is the most effective technique to target therapeutics to the heart territory most at risk from an infarct.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Reem Assi, Jolien Quintiens, Silvia Monteagudo, Rik J. J. Lories
Summary: Osteoarthritis is a chronic joint disease characterized by progressive damage to the joints, causing pain and loss of function. Intra-articular drug therapy has emerged as a potential treatment option, with drugs being injected directly into affected joints to optimize drug bioavailability and reduce systemic toxicity. This review explores the current landscape of intra-articular drug therapies for osteoarthritis, including established approaches and those in clinical development. Despite challenges in defining outcome measures and optimizing clinical trial set-ups, advancements in drug development and clinical trial design hold promise for successful therapies for this important disease.
Review
Immunology
Kely C. Matteucci, Andre A. S. Correa, Diego L. Costa
Summary: Tuberculosis and malaria are major causes of death due to infectious diseases worldwide. While both diseases can be treated with drugs, issues such as treatment compliance and drug resistance have hindered efforts to combat them. Recent research has shown that certain host biological processes play a role in the development of these diseases. Host-directed therapies, which can be administered alongside standard drug treatments, aim to speed up pathogen elimination and reduce harmful side effects caused by inflammation.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Pharmacology & Pharmacy
Liqing Hu, Congke Zhao, Zhuo Chen, Gaoyun Hu, Xiaohui Li, Qianbin Li
Summary: Pulmonary arterial hypertension (PAH) is a disease with limited therapeutic options and high complexity. Current treatments primarily focus on vasodilation rather than on vascular remodeling. Therefore, exploring new treatment strategies with dual effects on vasoconstriction and vascular remodeling is necessary.
DRUG DISCOVERY TODAY
(2022)
Review
Pharmacology & Pharmacy
Nathan Kauffman, James Morrison, Kevin O'Brien, Jinda Fan, Kurt R. Zinn
Summary: A paradigm shift is occurring in cancer diagnosis and therapy with radiopharmaceuticals. This strategy involves using diagnostic imaging to measure tumor uptake of radioactive agent X to select patients for therapy with radioactive agent Y. X-Y pairs, known as radiotheranostics, are being evaluated for intra-arterial dosing to enhance tumor targeting and improve imaging and therapy. Clinical trials are underway to assess these new therapeutic approaches, including the use of alpha-particle therapy with short-lived radioisotopes.
Review
Pediatrics
Li Li, Xinyu Zhu, Xiaojie Chen, Jieyun Gao, Chunchun Ding, Min Zhang, Shixun Ma
Summary: Pulmonary arterial hypertension (PAH) is a rare and devastating disease in infants and children. Current treatment approaches are mostly based on adult guidelines and clinical experience, but the advent of targeted drugs has improved the treatment of PAH in children. However, more research is needed to evaluate the combination of drugs, treatment strategies, and clinical endpoints in children PAH.
EUROPEAN JOURNAL OF PEDIATRICS
(2023)
Letter
Oncology
Julien Edeline, Yan Rolland, Boris Campillo-Gimenez, Heloise Bourien, Marion Trochet, Etienne Garin, Karim Boudjema
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jules Gregory, Lambros Tselikas, Caroline Allimant, Thierry de Baere, Irene Bargellini, Jon Bell, Jose Ignacio Bilbao, Antoine Bouvier, Julius Chapiro, Carlo Chiesa, Thomas Decaens, Alban Denys, Rafael Duran, Julien Edeline, Etienne Garin, Julien Ghelfi, Thomas Helmberger, Farah Irani, Marnix Lam, Robert Lewandowski, David Liu, Romaric Loffroy, David C. Madoff, Charles Mastier, Riad Salem, Bruno Sangro, Daniel Sze, Valerie Vilgrain, Michael Vouche, Boris Guiu, Maxime Ronot
Summary: This study aimed to define a textbook outcome (TO) for selective internal radiation therapy (SIRT) of hepatocellular carcinoma. The final TO, determined through expert opinions and an international survey, is a multidimensional standardization tool suitable for routine care, clinical round, and research.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Zhenggang Ren, Michel Ducreux, Ghassan K. Abou-Alfa, Philippe Merle, Weijia Fang, Julien Edeline, Zhiwei Li, Lihua Wu, Eric Assenat, Sheng Hu, Lorenza Rimassa, Tao Zhang, Jean-Frederic Blanc, Hongming Pan, Paul Ross, Chia-Jui Yen, Albert Tran, Guoliang Shao, Mohamed Bouattour, Yajin Chen, Tim Meyer, Jinlin Hou, David Tougeron, Yuxian Bai, Ming-Mo Hou, Zhiqiang Meng, John Wu, Vincent Li, Sandra Chica-Duque, Ann-Lii Cheng
Summary: Tislelizumab demonstrated durable antitumor activity and acceptable tolerability in previously treated advanced HCC patients, regardless of the number of prior lines of therapy.
Article
Medicine, General & Internal
C. Boitard, B. Clement, F. Michot, P. Miossec, P. Netter
Summary: University-hospitals have a triple mission of care, teaching and research. However, the evolution of these hospitals has drifted away from their founding principles, leading to a decrease in the effectiveness of high-level care for patients. In response to this observation, a symposium was held to evaluate research and innovation in health, make recommendations for necessary reforms in university hospitals and their role in a simplified organization of research in biology and health, and identify areas for further analysis.
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE
(2023)
Review
Oncology
Gael S. Roth, Cindy Neuzillet, Matthieu Sarabi, Julien Edeline, David Malka, Astrid Lievre
Summary: Cholangiocarcinoma is a deadly cancer with limited treatment options. Recent advances in immunotherapy have shown improved survival in the first-line treatment of advanced cholangiocarcinoma. Molecular profiling has identified targetable alterations, opening the way to personalized medicine. This review discusses recent clinical trial findings and the importance of systematic molecular screening for personalized treatment.
EUROPEAN JOURNAL OF CANCER
(2023)
Editorial Material
Gastroenterology & Hepatology
Julien Edeline, Jean-Frederic Blanc
LIVER INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Philippe Merle, Jean-Frederic Blanc, Julien Edeline, Karine Le Malicot, Manon Allaire, Eric Assenat, Meriem Guarssifi, Mohamed Bouattour, Jean-Marie Peron, Pierre Laurent-Puig, Massimo Levrero, Charlotte Costentin, Boris Guiu, Harry Sokol, David Tougeron, Thomas Aparicio, Jean-Charles Nault, Jean-Marc Phelip
Summary: The current first line systemic therapies for hepatocellular carcinoma are atezolizumab/bevacizumab and durvalumab/tremelimumab. However, the median overall survival is still below 20 months, and only a minority of patients become long-term survivors. The TRIPLET-HCC trial aims to evaluate the efficacy and safety of a triple combination therapy by adding ipilimumab to atezolizumab/bevacizumab compared to a double combination therapy.
DIGESTIVE AND LIVER DISEASE
(2023)
Editorial Material
Gastroenterology & Hepatology
Giuseppe Cabibbo, Julien Edeline
LIVER INTERNATIONAL
(2023)
Article
Oncology
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stephane Cattan, Yee Chao, Abby B. Siegel, Ivan Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Summary: With extended follow-up, pembrolizumab demonstrated continued improvement in overall survival (OS) and progression-free survival (PFS) compared to placebo in advanced hepatocellular carcinoma (HCC) patients previously treated with sorafenib. The adverse event profile of pembrolizumab remained consistent with placebo.
Article
Medicine, General & Internal
Alexandre Thobie, Fabien Robin, Benjamin Menahem, Jean Lubrano, Karim Boudjema, Arnaud Alves, Olivier Dejardin, Laurent Sulpice
Summary: This retrospective study focused on the impact of post-pancreatectomy hemorrhage (PPH) on long-term survival after pancreatoduodenectomy (PD) for cancer. The results showed that PPH significantly increased mortality rate and severe postoperative complication rate, but after 6 months, PPH had no impact on mortality.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Francois Villeret, Sebastien Dharancy, Domitille Erard, Armand Abergel, Louise Barbier, Camille Besch, Olivier Boillot, Karim Boudjema, Audrey Coilly, Filomena Conti, Christophe Corpechot, Christophe Duvoux, Francois Faitot, Stephanie Faure, Claire Francoz, Emiliano Giostra, Jean Gugenheim, Jean Hardwigsen, Marie-Noelle Hilleret, Jean-Baptiste Hiriart, Pauline Houssel-Debry, Nassim Kamar, Guillaume Lassailly, Marianne Latournerie, Georges-Philippe Pageaux, Didier Samuel, Claire Vanlemmens, Faouzi Saliba, Jerome Dumortier
Summary: This study evaluated the risk of disease recurrence after liver transplantation for non-alcoholic fatty liver disease (NAFLD) and identified several factors influencing recurrence. The study found a high cumulative recurrence rate of steatosis, steatohepatitis, and fibrosis after transplantation for NAFLD. Age at transplantation, post-transplant high-density lipoprotein-cholesterol level, and steatosis grade were significant risk factors for recurrence. The study highlights the need for further evaluation of preventive measures for disease recurrence after transplantation for NAFLD.
Article
Gastroenterology & Hepatology
Cyrille Feray, Loic Campion, Philippe Mathurin, Isabelle Archambreaud, Xavier Mirabel, Jean Pierre Bronowicki, Emmanuel Rio, Christophe Perret, Laurent Mineur, Frederic Oberti, Yann Touchefeu, Jerome Gournay, Helen Regnault, Julien Edeline, Agnes Rode, Patrick Hillion, Jean Frederic Blanc, Eric Nguyen Khac, Daniel Azoulay, Alain Luciani, Athena Galetto Preglisasco, Elodie Faurel-Paul, Helene Auble, Francoise Mornex, Philippe Merle
Summary: This study compared the efficacy and safety of the combination of a single TACE and external CRT vs. classical TACE. The results showed that the combination of TACE + CRT failed to improve liver PFS or overall survival and led to more frequent liver-related adverse effects.
Article
Gastroenterology & Hepatology
Julien Edeline, John Bridgewater, Boris Campillo-Gimenez, Estelle Neveu, Jean-Marc Phelip, Cindy Neuzillet, Karim Boudjema, Yan Rolland, Juan W. Valle, Etienne Garin, David Malka, Angela Lamarca
Summary: The study suggests that SIRT combined with chemotherapy may improve outcomes over chemotherapy alone for patients with advanced, liver-only intrahepatic cholangiocarcinoma (iCCA). Further randomized controlled trials are needed to confirm these findings.
Review
Oncology
Victoria Foy, Mairead G. McNamara, Juan W. Valle, Angela Lamarca, Julien Edeline, Richard A. Hubner
Summary: This review explores the current evidence for immune checkpoint inhibition (ICI) in patients with advanced HCC and discusses future directions, including the need for predictive biomarkers, the impact of cirrhosis etiology on treatment response, and the safety of ICI in patients with impaired liver function.